In short: Giroux: "amazing" long-term setup — the leader in siRNA drugs silencing TTR (an underdiagnosed cardiovascular condition); best drug today, an even better best-in-class product in 2028–30 giving patent-protected growth through 2045, plus an underappreciated siRNA pipeline with multiple potential blockbusters. $37B cap makes a takeout less likely, but "if I were the CEO of Merck or Eli Lilly, I would buy it in a heartbeat" (~$80B would be a win-win); one of the best large-pharma performers of the next decade regardless.
Alnylam leads a field called RNA silencing — drugs that switch off the specific gene causing a disease. Its franchise treats a widely underdiagnosed heart condition (TTR amyloidosis); it has the best drug today and an even better one coming in 2028–30, with patent protection out to 2045, plus a pipeline that could produce several more blockbusters. At $37 billion it's a big bite for an acquirer, but Giroux says if he ran Merck or Lilly he'd "buy it in a heartbeat" — and even unacquired, he expects it to be one of the decade's best-performing large pharma stocks.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.